<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2020-24-3-64-71</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-1828</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Особенности течения нефрита, ассоциированного с IgА-васкулитом Шенлейна-Геноxа у детей</article-title><trans-title-group xml:lang="en"><trans-title>Characteristics of the course of nephritis associated with Iga-vasculitis Henoch-Schoenlein in children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3434-5392</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сукало</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukalo</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф., академик Сукало Александр Васильевич, д-р мед. наук, 1-я кафедра детских болезней, заведующий кафедрой</p><p>220116, Беларусь, г. Минск, пр. Дзержинского, д. 83</p><p>Тел.: +375(17)369-57-61</p></bio><bio xml:lang="en"><p>Prof., Academic Alexander V. Sukalo, MD, PhD, DMedSci, 1st Department of Pediatrics, Cheif</p><p>220116, Belarus, Minsk, av. Dzerzhynskogo 83</p><p>Phone: +375(17)369-57-61</p></bio><email xlink:type="simple">kozyroia@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8915-445X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козыро</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazyra</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доц. Козыро Инна Александровна, канд. мед. наук, 1-я кафедра детских болезней</p><p>220116, Беларусь, г. Минск, пр. Дзержинского, д. 83</p><p>Тел.: +375(17)369-57-61</p></bio><bio xml:lang="en"><p>Associate Professor Ina A. Kazyra, MD, PhD, 1st Department of Pediatrics</p><p>220116, Belarus, Minsk, av. Dzerzhynskogo 83</p><p>Phone: +375(17)369-57-61</p></bio><email xlink:type="simple">kozyroia@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Белорусский государственный медицинский университет</institution><country>Беларусь</country></aff><aff xml:lang="en"><institution>Belarussian State Medical University</institution><country>Belarus</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2020</year></pub-date><volume>24</volume><issue>3</issue><fpage>64</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сукало А.В., Козыро И.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Сукало А.В., Козыро И.А.</copyright-holder><copyright-holder xml:lang="en">Sukalo A.V., Kazyra I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/1828">https://journal.nephrolog.ru/jour/article/view/1828</self-uri><abstract><sec><title>ВВЕДЕНИЕ</title><p>ВВЕДЕНИЕ. Среди системных вазопатий у детей IgA-васкулит Шенлейна-Геноxа (ШГ) относится к наиболее распространенным, по данным разных авторов поражение почек при нем отмечается в 25–80 % случаев и обычно определяет прогноз заболевания.</p><p>ЦЕЛЬЮ исследования явился анализ клинических, лабораторных, иммунологических, морфологических характеристик, особенностей течения и лечения нефрита при IgА-васкулите ШГ у детей, а также факторов, влияющих на прогноз.</p></sec><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. В исследование включен 31 пациент с морфологически верифицированным нефритом вследствие IgA-васкулита ШГ (18 – мальчиков, 13 – девочек) в возрасте от 3 до 17 лет, находившихся под наблюдением в нефрологическом отделении УЗ «2-я детская городская клиническая больница» Республиканского Центра детской нефрологии и почечной заместительной терапии г. Минска в период с 2010 по 2019 г. Проанализированы: клинический вариант поражения почек, лабораторные параметры (включая исследование молекул активации лимфоцитов BAFF, RANTES, провоспалительныx IL1β, caspase1, TNFα, факторов роста VEGF, TGF), суточный мониторинг и разовые офисные измерения артериального давления, результаты ЭХО-кардиографии с расчетом индексов, УЗИ сонных артерий с оценкой толщины комплекса интима–медиа, морфологические изменения в почечной ткани, а также схемы лечения.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Показано участие deGal-IgA1, маркеров активации Т- и В-лимфоцитов, провоспалительных и профибротических молекул в развитии болезни. АГ зарегистрирована у 42 % детей, признаки кардиоремоделирования по результатам расчётных индексов у 19,3 %. Снижение уровня адипонектина, витамина D, лептина, повышение обестатина, Pro-BNP, hs-CRP, показателя TSAT позволяет отнести пациентов с нефритом вследствие IgА-васкулита ШГ в группу умеренного риска развития кардиоваскулярных нарушений, что предполагает необходимость своевременной коррекции.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. В большинстве случаев нефрит при IgА-васкулите ШГ характеризовался доброкачественным течением, редкими рецидивами, прогрессирование до терминальной стадии хронической болезни почек отмечалось в 6,5 %.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>INTRODUCTION</title><p>INTRODUCTION. Among systemic vasopathies in children, IgA vasculitis Henoch Schoenlein (HS) is the most common, according to various authors, kidney damage is noted in 25-80 % and usually determines the prognosis of the disease.</p><p>THE AIM of the study was to analyze clinical, laboratory, immunological, morphological characteristics, features of the course and treatment of nephritis associated with IgA vasculitis HS in children, as well as factors affecting the prognosis.</p></sec><sec><title>PATIENTS AND METHODS</title><p>PATIENTS AND METHODS. The study included 31 patients with morphologically verified nephritis due to IgA vasculitis HS (18 – boys, 13 – girls) aged 3 to 17 years, who were monitored at the Nephrology Department of the "2nd Children's City Clinical Hospital" of the National Center for Pediatric Nephrology and Renal Replacement therapy in Minsk from 2010 to 2019 yrs.The following parameters were analyzed: the clinical variant of kidney damage, laboratory tests (including the study of BAFF, RANTES lymphocyte activation molecules, pro-inflammatory IL1β, caspase1, TNFα, growth factors VEGF, TGF), 24 hours monitoring and office blood pressure measurements, ECHO cardiography with indicescalculation, ultrasound of the carotid arteries with the thickness of intima-media complex, morphological changes in the renal tissue, as well as treatment regimens.</p></sec><sec><title>RESULTS</title><p>RESULTS. The contribution of deGal-IgA1, markers of T and B lymphocytes activation, pro-inflammatory and profibrotic molecules in the development of the disease is shown. Arterial hypertension was registered in 42 % of children, signs of heart remodeling according to the calculated indices in 19,3 %. Decrease level of adiponectin, vitamin D, leptin, increase concentration of obestatin, Pro-BNP, hs-CRP, and TSAT indicator classify patients with nephritis due to IgA vasculitis HS at moderate risk for the developmentof cardio-vascular disorders, which suggests the need for timely correction.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. In most cases, nephritis with IgA vasculitis HS has a benign course with rare relapses and progression to the end stage of chronic kidney disease (6,5 %).</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>IgА-васкулит Шенлейна-Геноxа</kwd><kwd>нефрит</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>IgA-vasculitis Henoch Schoenlein</kwd><kwd>nephritis</kwd><kwd>children</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jennette JC.Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol2013;17(5):603–606. doi: 10.1007/s10157-013-0869-6</mixed-citation><mixed-citation xml:lang="en">Jennette JC.Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol2013;17(5):603–606. doi: 10.1007/s10157-013-0869-6</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ozen S, Pistorio A, Iusan SM et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.Ann Rheum Dis2010;69(5):798–806. doi: 10.1136/ard.2009.116657</mixed-citation><mixed-citation xml:lang="en">Ozen S, Pistorio A, Iusan SM et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.Ann Rheum Dis2010;69(5):798–806. doi: 10.1136/ard.2009.116657</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Савенкова НД. Стратегия терапии ANCA-ассоциированного васкулита у детей и подростков. Нефрология 2019; 23(5):106–115. doi: 10.24884/1561-6274-2019-23-5-107-115</mixed-citation><mixed-citation xml:lang="en">Savenkova ND. Treatment strategy ANCA-associated renal vasculitides in children and adolescents. Nephrology (Saint-Petersburg) 2019;23(5):107–115. (In Russ.) doi: 10.24884/1561-6274-2019-23-5-107-115</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Детская нефрология: рук. для врачей. Под ред. МС Игнатовой: 3-е издание, 2011; 692 с.</mixed-citation><mixed-citation xml:lang="en">Pediatric nephrology: hands. for doctors. Ed. MS Ignatova: 3rd edition, 2011; 692 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol2014;10(10):563–573. doi: 10.1038/nrneph.2014.126</mixed-citation><mixed-citation xml:lang="en">Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol2014;10(10):563–573. doi: 10.1038/nrneph.2014.126</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Naija O, Bouzaraa J, Goucha-Louzir R, Gargah T.Henoch Schonlein nephrites in children: clinical features and outcome: about 34 cases. Tunis Med 2013;91(12):700–704</mixed-citation><mixed-citation xml:lang="en">Naija O, Bouzaraa J, Goucha-Louzir R, Gargah T.Henoch Schonlein nephrites in children: clinical features and outcome: about 34 cases. Tunis Med 2013;91(12):700–704</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wozniak A, Pluta-Hadas K, Zurawski Jet al. Electron-microscopic and immunohistochemical study in Henoch-Schoenlein nephritis. Ultrastruct Pathol 2013;37(1):83–92. doi: 10.3109/01913123.2012.670035</mixed-citation><mixed-citation xml:lang="en">Wozniak A, Pluta-Hadas K, Zurawski Jet al. Electron-microscopic and immunohistochemical study in Henoch-Schoenlein nephritis. Ultrastruct Pathol 2013;37(1):83–92. doi: 10.3109/01913123.2012.670035</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Oni L, Sampath S. Childhood IgA Vasculitis (Henoch Schonlein Purpura)-Advances and Knowledge Gaps. Front Pediatr201927;7:257. doi: 10.3389/fped.2019.00257</mixed-citation><mixed-citation xml:lang="en">Oni L, Sampath S. Childhood IgA Vasculitis (Henoch Schonlein Purpura)-Advances and Knowledge Gaps. Front Pediatr201927;7:257. doi: 10.3389/fped.2019.00257</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Spasojević-Dimitrijeva B, Kostić M, Peco-Antić A et al. Henoch-Schönlein purpura outcome in children: a ten-year clinical study. Srp Arh Celok Lek2011;139(3-4):174–178</mixed-citation><mixed-citation xml:lang="en">Spasojević-Dimitrijeva B, Kostić M, Peco-Antić A et al. Henoch-Schönlein purpura outcome in children: a ten-year clinical study. Srp Arh Celok Lek2011;139(3-4):174–178</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr2015;11(1):29–34. doi: 10.1007/s12519-014-0534-5</mixed-citation><mixed-citation xml:lang="en">Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr2015;11(1):29–34. doi: 10.1007/s12519-014-0534-5</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jelusic M, Sestan M, Cimaz R, Ozen S. Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? Pediatr Rheumatol Online J2019;17(1):10. doi: 10.1186/s12969-019-0311-z</mixed-citation><mixed-citation xml:lang="en">Jelusic M, Sestan M, Cimaz R, Ozen S. Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? Pediatr Rheumatol Online J2019;17(1):10. doi: 10.1186/s12969-019-0311-z</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health2013;49(12):995–1003. doi: 10.1111/jpc.12403</mixed-citation><mixed-citation xml:lang="en">Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health2013;49(12):995–1003. doi: 10.1111/jpc.12403</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kawasaki Y, Ono A, Ohara S et al. Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment. Fukushima J Med Sci2013;59(1):15–26</mixed-citation><mixed-citation xml:lang="en">Kawasaki Y, Ono A, Ohara S et al. Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment. Fukushima J Med Sci2013;59(1):15–26</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kiryluk K, Moldoveanu Z, Sanders JT et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int 2011;80(1):79–87. doi: 10.1038/ki.2011.16</mixed-citation><mixed-citation xml:lang="en">Kiryluk K, Moldoveanu Z, Sanders JT et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int 2011;80(1):79–87. doi: 10.1038/ki.2011.16</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pillebout E, Jamin A, Ayari H et al. Biomarkers of IgA vasculitis nephritis in children. PLoS One2017;12(11):e0188718. doi: 10.1371/journal.pone.0188718</mixed-citation><mixed-citation xml:lang="en">Pillebout E, Jamin A, Ayari H et al. Biomarkers of IgA vasculitis nephritis in children. PLoS One2017;12(11):e0188718. doi: 10.1371/journal.pone.0188718</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shi D, Chan H, Yang Xet al. Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis. PLoS One 2019;14(10):e0223218. doi: 10.1371/journal.pone.0223218</mixed-citation><mixed-citation xml:lang="en">Shi D, Chan H, Yang Xet al. Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis. PLoS One 2019;14(10):e0223218. doi: 10.1371/journal.pone.0223218</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Beck L, Bomback AS, Choi MJ et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulo-nephritis. Am J Kidney Dis 2013;62(3):403–441. doi: 10.1053/j.ajkd.2013.06.002</mixed-citation><mixed-citation xml:lang="en">Beck L, Bomback AS, Choi MJ et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulo-nephritis. Am J Kidney Dis 2013;62(3):403–441. doi: 10.1053/j.ajkd.2013.06.002</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ozen S, Marks SD, Brogan P et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford)2019;58(9):1607–1616. doi: 10.1093/rheumatology/kez041</mixed-citation><mixed-citation xml:lang="en">Ozen S, Marks SD, Brogan P et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford)2019;58(9):1607–1616. doi: 10.1093/rheumatology/kez041</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
